All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APG-115,Toripalimab
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
APG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2 protein. APG-115 is the first MDM2-p53 inhibitor entering clinical development in China, with multiple ongoing clinical studies in solid tumors and hematologic malignancies in Chinaand the US.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Humanized anti-claudin18.2 autologous Chimeric Antigen Receptor T Cells
Therapeutic Area: Oncology Product Name: CT041
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
The initiation of an open label, multicenter, Phase 1b clinical trial to evaluate the safety and efficacy of autologous CT041 cell therapy in patients with advanced gastric, gastroesophageal, or pancreatic adenocarcinoma is currently underway.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APG-115
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
APG-115 has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 PPI.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GLR2007
Therapeutic Area: Oncology Product Name: GLR2007
Highest Development Status: Phase I/ Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2020
Details:
GLR2007 is a CDK 4/6 inhibitor that Gan & Lee is developing for the treatment of advanced solid tumors. The Gan & Lee GLR2007 Phase 1 clinical trial is currently enrolling patients to establish the safety, tolerability, and optimal dosing strategy of GLR2007.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APG-2575,Rituximab
Therapeutic Area: Oncology Product Name: APG-2575
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2020
Details:
This is the second ODD granted for APG-2575, following the previous ODD granted by the FDA in July for the treatment of Waldenström Macroglobulinemia (WM).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pamiparib,Temozolomide
Therapeutic Area: Oncology Product Name: BGB-290
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
Clinical and nonclinical data on its anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in two mini oral presentations and five posters at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APG-2575
Therapeutic Area: Oncology Product Name: APG-2575
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
The U.s FDA has granted APG-2575, a novel Bcl-2 inhibitor being developed by the company, an Orphan Drug Designation (ODD) for the treatment of Waldenström macroglobulinemia (WM).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EMB-01
Therapeutic Area: Oncology Product Name: EMB-01
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
The data presented in the poster characterizes EMB-01, EpimAb’s lead bispecific antibody candidate developed based the company’s proprietary FIT-Ig® platform to target EGFR and cMet on tumor cells simultaneously.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Beigene-283,Mirdametinib
Therapeutic Area: Oncology Product Name: BGB-283
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: SpringWorks Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
BeiGene provided a program update on their ongoing Phase 1b/2 study evaluating the combination of BeiGene’s investigational RAF dimer inhibitor, lifirafenib, with SpringWorks’ MEK inhibitor, mirdametinib, in solid tumors harboring mutations in the MAPK pathway.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TJD5
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Details:
Phase 1/2 study is a multicenter, open-label, dose escalation and cohort expansion study, which will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TJD5.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
